The Development of the HER2-Specific Inhibitor ONT-380 for Breast Cancer

July 26, 2014
Robert L. Kirkman, MD

Robert L. Kirkman, MD, President and CEO, Oncothyreon, discusses the development of ONT-380, an oral HER2-specific inhibitor, for the treatment of patients with HER2-positive metastatic breast cancer.

Clinical Pearls

Robert L. Kirkman, MD, President and CEO, Oncothyreon, discusses the development of ONT-380, an oral HER2-specific inhibitor, for the treatment of patients with HER2-positive metastatic breast cancer.

  • ONT-380 is being evaluated for the treatment of HER2-positive breast cancer in combination with T-DM1 and in combination with capecitabine and trastuzumab.
  • This agent is well tolerated. EGFR-related side effects have not been observed.
  • In a highly-pretreated population of patients with HER2-positive breast cancer, ONT-380 elicited a clinical benefit rate of 27%.